Go Pro
→ The smarter SpaceX play most investors will miss (From Crypto 101 Media) (Ad)tc pixel Free TARA Stock Alerts

Protara Therapeutics (TARA) Financials

Protara Therapeutics logo
$4.08 -0.02 (-0.37%)
As of 02:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Protara Therapeutics

Annual Income Statements for Protara Therapeutics

This table shows Protara Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -21 -29 -37 -21 -7.83 -34 -47 -66 -40 -45 -57
Consolidated Net Income / (Loss)		 -21 -29 -30 -21 -7.83 -34 -47 -66 -40 -45 -57
Net Income / (Loss) Continuing Operations		 -22 -29 -30 -21 -7.83 -34 -47 -66 -40 -45 -57
Total Pre-Tax Income 		-22 -29 -30 -21 -7.83 -34 -47 -66 -40 -45 -57
Total Operating Income		 -21 -29 -30 -21 -7.83 -34 -47 -67 -44 -49 -65
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 21 29 30 21 7.83 34 47 67 44 49 65
Selling, General & Admin Expense		 8.49 9.84 8.68 9.52 3.95 22 26 21 19 17 22
Research & Development Expense		 12 19 22 12 3.88 12 21 17 25 32 43
Total Other Income / (Expense), net		 -1.10 0.18 0.40 0.64 0.00 0.47 0.47 1.11 3.19 4.56 7.11
Interest & Investment Income		 0.14 0.19 0.26 0.44 - 0.50 0.24 1.11 3.19 4.17 6.38
Other Income / (Expense), net		 -1.24 -0.01 0.14 0.21 0.00 - 0.24 - 0.00 0.39 0.73
Basic Earnings per Share		 ($1.30) ($1.72) ($2.13) ($45.80) ($3.04) ($4.70) ($4.21) ($5.86) ($3.57) ($2.17) ($1.34)
Weighted Average Basic Shares Outstanding		 16.46M 16.56M 17.27M 452.56K 2.58M 7.23M 11.23M 11.26M 11.33M 20.59M 42.84M
Diluted Earnings per Share		 ($1.30) ($1.72) ($2.13) ($45.80) ($3.04) ($4.70) - - ($3.57) ($2.17) ($1.34)
Weighted Average Diluted Shares Outstanding		 16.46M 16.56M 17.27M 452.56K 2.58M 7.23M 11.23M 11.31M 11.33M 20.59M 42.84M
Weighted Average Basic & Diluted Shares Outstanding		 16.46M 16.56M 17.27M 452.56K 2.58M 7.23M 11.23M 11.31M 11.43M 36.77M 54.08M

Quarterly Income Statements for Protara Therapeutics

This table shows Protara Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.86 -10 -11 -9.51 -11 -13 -12 -15 -13 -17 -18
Consolidated Net Income / (Loss)		 -9.86 -10 -11 -9.51 -11 -13 -12 -15 -13 -17 -18
Net Income / (Loss) Continuing Operations		 -9.86 -10 -11 -9.51 -11 -13 -12 -15 -13 -17 -18
Total Pre-Tax Income 		-9.86 -10 -11 -9.51 -11 -13 -12 -15 -13 -17 -18
Total Operating Income		 -11 -11 -12 -11 -12 -14 -14 -17 -15 -19 -20
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 11 11 12 11 12 14 14 17 15 19 20
Selling, General & Admin Expense		 4.48 4.66 4.10 4.27 4.26 4.81 4.98 5.82 5.17 5.96 6.07
Research & Development Expense		 6.22 6.38 7.75 6.39 8.07 9.50 9.15 11 9.59 13 14
Total Other Income / (Expense), net		 0.84 0.82 0.76 1.15 1.11 1.54 2.21 1.63 1.50 1.77 1.85
Interest & Investment Income		 0.84 0.82 0.76 1.15 1.11 1.16 1.73 1.63 1.50 1.52 1.85
Other Income / (Expense), net		 - - 0.00 0.00 0.00 - 0.48 0.00 0.00 0.25 0.00
Basic Earnings per Share		 ($0.87) ($0.90) ($0.97) ($0.45) ($0.50) ($0.25) ($0.29) ($0.35) ($0.31) ($0.39) ($0.31)
Weighted Average Basic Shares Outstanding		 11.35M 11.33M 11.42M 21.23M 22.33M 20.59M 40.71M 42.27M 42.27M 42.84M 57.54M
Diluted Earnings per Share		 ($0.87) - ($0.97) ($0.45) ($0.50) - ($0.29) ($0.35) ($0.31) ($0.39) ($0.31)
Weighted Average Diluted Shares Outstanding		 11.35M 11.33M 11.42M 21.23M 22.33M 20.59M 40.71M 42.27M 42.27M 42.84M 57.54M
Weighted Average Basic & Diluted Shares Outstanding		 11.36M 11.43M 20.59M 20.63M 20.63M 0.00 38.58M 38.58M 38.59M 0.00 56.20M

Annual Cash Flow Statements for Protara Therapeutics

This table details how cash moves in and out of Protara Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -29 -3.56 -15 -1.82 -4.99 169 -133 -12 15 123 -113
Net Cash From Operating Activities		 -18 -24 -22 -23 -5.01 -23 -35 -26 -38 -36 -56
Net Cash From Continuing Operating Activities		 -18 -24 -22 -23 -5.01 -23 -35 -26 -38 -36 -56
Net Income / (Loss) Continuing Operations		 -21 -29 -30 -21 -7.83 -34 -47 -66 -40 -45 -57
Consolidated Net Income / (Loss)		 -21 -29 -30 -21 -7.83 -34 -47 -66 -40 -45 -57
Depreciation Expense		 0.06 0.12 0.15 0.12 0.02 0.10 0.12 0.25 0.34 0.33 0.36
Amortization Expense		 0.65 0.13 -0.00 -0.05 0.00 0.00 1.74 1.14 -0.44 -0.69 -1.25
Non-Cash Adjustments To Reconcile Net Income		 2.78 3.29 3.05 3.40 0.42 9.84 11 38 7.11 5.13 3.83
Changes in Operating Assets and Liabilities, net		 0.33 1.29 4.41 -5.97 2.38 0.57 -0.52 0.54 -4.14 4.01 -1.82
Net Cash From Investing Activities		 -11 20 -16 18 -0.48 2.84 -98 15 53 19 -139
Net Cash From Continuing Investing Activities		 -11 20 -16 18 -0.48 2.84 -98 15 53 19 -139
Purchase of Property, Plant & Equipment		 -0.20 -0.27 -0.04 -0.12 -0.48 -0.88 -0.60 -0.12 -0.05 -0.06 -0.09
Purchase of Investments		 -89 -40 -33 -15 - 0.00 -125 -44 -12 -29 -205
Sale and/or Maturity of Investments		 78 60 17 34 - - 27 59 65 49 65
Net Cash From Financing Activities		 0.16 0.21 23 2.99 0.50 189 -0.23 -0.09 -0.09 140 83
Net Cash From Continuing Financing Activities		 0.16 0.21 23 2.99 0.50 189 -0.23 -0.09 -0.09 140 84
Issuance of Debt		 - - - - - - - - - - 81
Issuance of Common Equity		 0.08 0.01 1.42 2.99 0.50 88 - - 0.00 42 0.00
Other Financing Activities, net		 0.09 0.20 0.11 - 0.00 78 - - -0.09 98 2.55
Cash Interest Paid		 - - - - 0.00 0.03 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 - - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Protara Therapeutics

This table details how cash moves in and out of Protara Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.21 5.82 13 37 -38 111 -71 -60 -19 37 -35
Net Cash From Operating Activities		 -6.56 -8.70 -10 -7.69 -8.43 -9.31 -15 -12 -12 -17 -21
Net Cash From Continuing Operating Activities		 -6.56 -8.70 -10 -7.69 -8.43 -9.31 -15 -12 -12 -17 -22
Net Income / (Loss) Continuing Operations		 -9.86 -10 -11 -9.51 -11 -13 -12 -15 -13 -17 -18
Consolidated Net Income / (Loss)		 -9.86 -10 -11 -9.51 -11 -13 -12 -15 -13 -17 -18
Depreciation Expense		 0.08 0.11 0.08 0.08 0.08 0.08 0.08 0.10 0.09 0.09 0.09
Non-Cash Adjustments To Reconcile Net Income		 1.48 1.75 1.47 1.31 1.19 1.16 0.90 1.17 1.32 0.24 0.65
Changes in Operating Assets and Liabilities, net		 1.87 -0.23 -0.77 0.44 1.85 2.50 -3.81 1.81 -0.21 0.39 -4.80
Net Cash From Investing Activities		 6.38 15 23 2.95 -29 23 -58 -48 -6.51 -27 -15
Net Cash From Continuing Investing Activities		 6.38 15 23 2.95 -29 23 -58 -48 -6.51 -27 -15
Purchase of Property, Plant & Equipment		 -0.04 - 0.00 -0.06 -0.01 - -0.04 -0.02 -0.00 -0.02 0.00
Purchase of Investments		 - - 0.00 - -29 - -66 -52 -24 -63 -44
Sale and/or Maturity of Investments		 6.42 15 23 3.00 - 23 7.50 4.00 18 36 29
Net Cash From Financing Activities		 -0.03 - -0.08 42 - 98 1.73 0.01 0.01 81 1.14
Net Cash From Continuing Financing Activities		 -0.03 - -0.08 42 - 98 1.73 0.01 0.01 82 1.94
Other Financing Activities, net		 -0.03 - -0.08 0.13 - 3.81 1.73 0.01 0.01 0.80 1.94

Annual Balance Sheets for Protara Therapeutics

This table presents Protara Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 68 44 44 24 1.22 203 173 113 79 181 209
Total Current Assets		 67 43 43 23 0.76 169 93 86 69 172 160
Cash & Equivalents		 40 36 21 19 0.56 169 36 24 40 163 50
Short-Term Investments		 25 4.93 21 2.50 - 0.00 56 60 26 7.49 106
Prepaid Expenses		 1.35 1.44 1.34 1.37 0.08 0.79 1.88 1.78 3.13 1.86 3.95
Plant, Property, & Equipment, net		 0.22 0.37 0.26 0.26 0.46 1.24 1.72 1.59 1.30 1.03 0.76
Total Noncurrent Assets		 0.71 0.39 0.24 0.02 0.00 32 78 26 8.95 8.27 49
Long-Term Investments		 - - - - - 0.00 39 18 - 0.00 42
Other Noncurrent Operating Assets		 0.71 0.39 0.24 0.02 0.00 2.97 8.78 7.67 8.95 8.27 6.87
Total Liabilities & Shareholders' Equity		 68 44 44 24 1.22 203 173 113 79 181 209
Total Liabilities		 4.13 5.08 9.24 3.08 3.35 3.91 11 11 11 14 13
Total Current Liabilities		 4.13 5.08 9.24 3.08 3.35 2.92 4.30 5.74 6.15 11 11
Accounts Payable		 1.02 0.56 0.29 0.44 0.72 0.91 0.95 1.59 2.43 4.43 3.47
Accrued Expenses		 2.58 4.52 8.95 2.64 2.64 1.91 2.49 3.24 2.73 5.41 6.23
Other Current Liabilities		 0.54 - - - 0.00 0.09 0.86 0.92 0.98 1.12 1.24
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 1.00 6.38 5.47 4.48 3.36 2.12
Other Noncurrent Operating Liabilities		 - - - - 0.00 1.00 6.38 5.47 4.48 3.36 2.12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 63 38 35 20 -2.13 199 162 102 68 167 196
Total Preferred & Common Equity		 63 38 35 20 -2.13 199 162 102 68 167 196
Preferred Stock		 0.00 0.00 0.00 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 63 38 35 -1.08 -2.13 199 162 102 68 167 196
Common Stock		 195 198 203 209 11 246 256 263 269 412 499
Retained Earnings		 -131 -160 -190 -210 -13 -47 -94 -160 -200 -245 -302
Accumulated Other Comprehensive Income / (Loss)		 -0.01 0.00 -0.01 0.01 - 0.00 -0.21 -0.69 -0.03 0.00 0.09

Quarterly Balance Sheets for Protara Therapeutics

This table presents Protara Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 88 68 102 94 169 157 145 192
Total Current Assets		 78 58 92 85 127 125 136 140
Cash & Equivalents		 34 52 90 52 91 31 13 15
Short-Term Investments		 40 2.99 0.00 30 33 91 120 121
Prepaid Expenses		 3.78 2.69 2.63 3.58 2.17 2.88 2.97 4.21
Plant, Property, & Equipment, net		 1.40 1.21 1.19 1.11 0.99 0.91 0.83 0.67
Total Noncurrent Assets		 9.25 9.01 8.25 7.90 41 31 8.16 51
Long-Term Investments		 0.00 - - - 33 23 0.96 42
Other Noncurrent Operating Assets		 9.25 9.01 8.25 7.90 7.89 7.54 7.21 9.62
Total Liabilities & Shareholders' Equity		 88 68 102 94 169 157 145 192
Total Liabilities		 12 9.73 9.60 12 10 13 12 11
Total Current Liabilities		 6.78 5.50 5.65 8.64 7.02 9.76 9.91 8.92
Accounts Payable		 2.50 0.97 1.39 2.30 2.31 5.30 4.50 4.03
Accrued Expenses		 3.31 3.53 3.23 5.27 3.54 3.26 4.19 3.63
Other Current Liabilities		 0.97 1.00 1.04 1.08 1.17 1.20 1.22 1.26
Total Noncurrent Liabilities		 4.74 4.23 3.95 3.66 3.06 2.75 2.44 1.79
Other Noncurrent Operating Liabilities		 4.74 4.23 3.95 3.66 3.06 2.75 2.44 1.79
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 77 58 92 82 158 144 132 181
Total Preferred & Common Equity		 77 58 92 82 158 144 132 181
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 77 58 92 82 158 144 132 181
Common Stock		 267 270 313 314 415 416 417 502
Retained Earnings		 -190 -211 -221 -232 -257 -272 -285 -320
Accumulated Other Comprehensive Income / (Loss)		 -0.17 -0.00 0.00 0.03 0.09 0.08 0.14 -0.36

Annual Metrics And Ratios for Protara Therapeutics

This table displays calculated financial ratios and metrics derived from Protara Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 16,484,508.00 16,594,445.00 17,619,418.00 19,221,292.00 19,585,394.00 11,211,840.00 11,235,731.00 11,267,389.00 11,364,903.00 - 11,364,903.00
DEI Adjusted Shares Outstanding		 412,113.00 414,861.00 440,485.00 480,532.00 489,635.00 11,211,840.00 11,235,731.00 11,267,389.00 11,364,903.00 - 11,364,903.00
DEI Earnings Per Adjusted Shares Outstanding		 -51.87 -68.76 -83.34 -43.14 -15.99 -3.03 -4.21 -5.85 -3.56 - -5.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -1,153.78% -33.00% -5.66% 29.84% 62.97% -339.48% -32.20% -44.67% 33.44% -12.36% -31.72%
EBIT Growth		 -781.23% -29.89% -5.24% 29.97% 63.01% -339.90% -37.19% -41.92% 34.97% -11.82% -30.87%
NOPAT Growth		 -175.33% -37.54% -5.77% 29.61% 63.36% -339.90% -37.87% -41.22% 34.97% -12.70% -31.32%
Net Income Growth		 -539.65% -33.44% -5.04% 30.82% 62.23% -333.95% -39.07% -39.58% 38.71% -10.33% -28.80%
EPS Growth		 58.86% -32.31% -23.84% 30.82% 62.23% -54.61% 0.00% 0.00% 0.00% 39.22% 38.25%
Operating Cash Flow Growth		 -75.84% -34.85% 5.64% -3.94% 78.43% -367.11% -47.40% 23.32% -41.95% 4.66% -57.41%
Free Cash Flow Firm Growth		 -43.08% -37.37% 12.31% -25.17% 79.88% -1,262.40% 41.00% 54.08% -115.04% 14.75% -64.39%
Invested Capital Growth		 -63.70% -54.79% -157.37% 80.76% -89.04% 1,236.52% 2.04% -100.55% 1,684.39% -215.21% 53.20%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -176.87% -1.48% 3.92% 1.16% 26.83% -23.00% -1.37% -81.79% 39.28% -6.68% -8.25%
EBIT Q/Q Growth		 -164.35% -2.12% 4.64% 1.24% 26.79% -22.98% -2.37% -77.23% 39.49% -6.29% -8.33%
NOPAT Q/Q Growth		 -16.23% -2.42% 4.03% 0.95% 26.79% -22.98% -2.88% -77.23% 39.49% -7.13% -7.97%
Net Income Q/Q Growth		 -173.99% -2.22% 4.50% 1.39% 25.92% -22.31% -3.31% -77.23% 41.56% -6.06% -8.58%
EPS Q/Q Growth		 -102.05% -1.78% 1.84% 1.39% 25.92% -7.06% 0.00% 0.00% 0.00% 0.00% -11.67%
Operating Cash Flow Q/Q Growth		 -21.73% -1.69% -0.54% 5.63% 39.15% -32.02% -0.41% 6.64% -10.84% -1.73% -15.68%
Free Cash Flow Firm Q/Q Growth		 0.00% -2.12% -0.52% 3.61% 43.77% -14.84% 3.97% 41.52% -57.17% 3.32% -16.52%
Invested Capital Q/Q Growth		 -22.56% -17.20% 7.01% -6.19% -101.50% 5.35% -2.43% -100.54% -6.19% -1,181.51% -10.63%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 97.32% 100.00% 100.00% 100.00% 100.00% 100.00% 100.50% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.35% 99.33% 99.14% 97.94% 100.00% 98.65% 99.50% 98.34% 92.68% 91.45% 90.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.31% -56.02% -81.89% -75.13% -85.50% -34.48% -26.17% -49.96% -47.44% -37.88% -31.60%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -187.61% -109.57% 0.00% -1,220.11% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -29.31% -56.02% -81.89% -45.83% 14.98% -34.48% -26.17% -49.96% -47.44% -37.88% -31.60%
Return on Equity Simple (ROE_SIMPLE)		 -33.72% -74.21% -86.25% -101.40% 367.95% -17.05% -29.18% -64.61% -59.16% -26.68% 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -20 -21 -15 -5.48 -24 -33 -47 -31 -34 -45
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -9.09% -15.82% -20.87% -18.02% -20.94% -11.66% -9.36% -16.32% -11.79% -8.64% -6.66%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -44.68% -20.59% -23.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -29 -30 -21 -7.83 -34 -47 -67 -44 -49 -64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -28 -30 -21 -7.81 -34 -45 -66 -44 -49 -65
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.03 0.82 0.94 0.00 0.00 0.88 0.47 0.30 0.31 0.65 1.16
Price to Tangible Book Value (P/TBV)		 4.03 0.82 0.94 0.00 0.00 1.03 0.57 0.30 0.31 0.65 1.16
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.21 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.05 -1.14 -1.16 -1.22 -0.86 -0.83 -0.88 -0.98 -1.00 -1.01
Leverage Ratio		 1.04 1.09 1.20 1.22 1.35 1.04 1.04 1.08 1.13 1.11 1.08
Compound Leverage Factor		 1.04 1.08 1.19 1.20 1.35 1.02 1.04 1.07 1.05 1.01 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 105.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% -5.28% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 34.38 -2.56 -5.24 -6.46 -30.73 26.95 3.21 -1.46 -3.23 2.84 8.32
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 39.00% 117.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.12 8.42 4.71 7.55 0.23 58.13 21.66 15.01 11.17 15.71 14.58
Quick Ratio		 15.79 8.13 4.56 7.10 0.17 57.84 21.23 14.70 10.67 15.54 14.22
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -19 -17 -21 -4.21 -57 -34 -16 -33 -29 -47
Operating Cash Flow to CapEx		 -8,871.72% -8,740.59% -63,862.86% -19,523.53% -1,054.95% -2,647.85% -5,788.93% -22,047.50% -83,460.00% -56,838.10% -59,962.77%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1,688.17 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -688.44 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -714.44 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.86 -2.88 -7.40 -1.42 -2.69 31 31 -0.17 2.74 -3.16 -1.48
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.72 -1.02 -4.53 5.98 -1.27 33 0.62 -31 2.91 -5.90 1.68
Enterprise Value (EV)		 190 -9.85 -9.32 41 42 6.49 -55 -72 -44 -62 30
Market Capitalization		 255 31 33 41 42 175 76 30 21 109 228
Book Value per Share		 $3.85 $2.32 $1.97 ($0.06) ($0.11) $17.77 $14.41 $9.06 $6.01 $8.12 $4.59
Tangible Book Value per Share		 $3.85 $2.32 $1.97 ($0.06) ($0.11) $15.14 $11.78 $9.06 $6.01 $8.12 $4.59
Total Capital		 63 38 35 20 -2.13 199 162 102 68 167 196
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -65 -41 -42 -22 -0.56 -169 -131 -102 -66 -170 -198
Capital Expenditures (CapEx)		 0.20 0.27 0.04 0.12 0.48 0.88 0.60 0.12 0.05 0.06 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.79 -3.64 -7.90 -1.71 -3.15 -2.13 -2.42 -3.96 -3.02 -9.10 -6.99
Debt-free Net Working Capital (DFNWC)		 62 38 34 20 -2.59 167 89 80 63 161 149
Net Working Capital (NWC)		 62 38 34 20 -2.59 167 89 80 63 161 149
Net Nonoperating Expense (NNE)		 6.77 8.43 8.71 5.77 2.35 9.87 14 19 9.89 10 12
Net Nonoperating Obligations (NNO)		 -65 -41 -42 -22 -0.56 -169 -131 -102 -66 -170 -198
Total Depreciation and Amortization (D&A)		 0.71 0.25 0.15 0.06 0.02 0.10 1.85 1.39 -0.10 -0.35 -0.88
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($52.00) ($68.80) ($85.20) ($46.00) ($30.15) ($4.70) ($4.21) ($5.86) ($3.57) ($2.17) ($1.34)
Adjusted Weighted Average Basic Shares Outstanding		 412.70K 415.09K 441.87K 481.09K 5.84M 11.23M 11.25M 11.31M 11.33M 20.59M 42.84M
Adjusted Diluted Earnings per Share		 ($52.00) ($68.80) ($85.20) ($46.00) ($30.15) ($4.70) ($4.21) $0.00 $0.00 ($2.17) ($1.34)
Adjusted Weighted Average Diluted Shares Outstanding		 412.70K 415.09K 441.87K 481.09K 5.84M 11.23M 11.25M 11.26M 11.43M 20.59M 42.84M
Adjusted Basic & Diluted Earnings per Share		 ($52.00) ($68.80) ($85.20) ($46.00) ($30.15) ($4.70) ($4.21) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 411.60K 414.05K 431.86K 452.56K 497.28K 7.23M 11.23M 11.31M 11.43M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -20 -21 -15 -5.48 -24 -33 -26 -31 -34 -45
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1,013.06 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -709.14 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1,039.06 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -735.14 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.48% -0.14% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Protara Therapeutics

This table displays calculated financial ratios and metrics derived from Protara Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 11,329,080.00 11,364,903.00 11,364,903.00 11,364,903.00 11,364,903.00 - 11,364,903.00 11,364,903.00 11,364,903.00 11,364,903.00 11,364,903.00
DEI Adjusted Shares Outstanding		 11,329,080.00 11,364,903.00 11,364,903.00 11,364,903.00 11,364,903.00 - 11,364,903.00 11,364,903.00 11,364,903.00 11,364,903.00 11,364,903.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.87 -0.92 -0.98 -0.84 -0.99 - -1.05 -1.32 -1.17 -1.52 -1.56
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -40.74% 71.91% -21.69% 13.20% -17.02% -31.34% -15.97% -59.23% -19.81% -34.92% -42.35%
EBIT Growth		 -34.19% 72.05% -21.77% 12.18% -15.23% -29.63% -15.12% -55.58% -19.71% -35.22% -43.88%
NOPAT Growth		 -34.19% 72.05% -21.77% 12.18% -15.23% -29.63% -19.18% -55.58% -19.71% -33.31% -38.98%
Net Income Growth		 -28.20% 73.77% -22.66% 15.77% -13.78% -24.93% -7.38% -57.26% -18.17% -35.54% -49.25%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 42.53% 0.00% 70.10% 22.22% 38.00% -56.00% -6.90%
Operating Cash Flow Growth		 -22.70% -73.10% 19.47% 18.29% -28.55% -6.99% -41.76% -59.36% -47.64% -82.10% -45.06%
Free Cash Flow Firm Growth		 481.39% -384.97% 48.55% -126.27% -127.67% 61.29% -23.45% -57.03% -45.04% -264.99% -115.81%
Invested Capital Growth		 -90.90% 1,684.39% -39.54% -49.25% -90.01% -215.21% -69.62% -148.00% -557.53% 53.20% 291.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 11.87% -2.78% -7.14% 10.57% -18.82% -15.36% 2.80% -22.79% 10.60% -26.45% -2.55%
EBIT Q/Q Growth		 11.86% -3.19% -7.34% 10.04% -15.66% -16.07% 2.03% -21.57% 11.01% -27.57% -4.24%
NOPAT Q/Q Growth		 11.86% -3.19% -7.34% 10.04% -15.66% -16.07% 1.31% -17.43% 11.01% -29.26% -2.88%
Net Income Q/Q Growth		 12.70% -3.66% -8.55% 14.26% -17.93% -13.82% 6.70% -25.57% 11.38% -30.54% -2.74%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 53.61% -11.11% 0.00% -16.00% -20.69% 11.43% -25.81% 20.51%
Operating Cash Flow Q/Q Growth		 30.26% -32.60% -19.30% 25.94% -9.72% -10.36% -58.07% 16.74% -1.65% -36.12% -25.92%
Free Cash Flow Firm Q/Q Growth		 12.45% -149.07% 41.62% 18.46% -18.44% 31.35% -86.21% -3.72% -9.40% -72.74% -10.10%
Invested Capital Q/Q Growth		 -39.94% -6.19% 16.13% -22.43% -88.17% -1,181.51% 130.62% -222.54% -12.74% -10.63% 355.82%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 92.15% 92.57% 93.62% 89.23% 90.99% 89.22% 87.33% 90.20% 89.82% 91.91% 90.59%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -64.00% -47.44% -55.45% -45.90% -52.97% -37.88% -41.88% -43.02% -49.42% -31.60% -37.27%
Cash Return on Invested Capital (CROIC)		 -121.51% -1,220.11% -708.58% -779.41% -1,834.98% 0.00% -1,628.09% 0.00% 0.00% 0.00% -2,184.15%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -64.00% -47.44% -55.45% -45.90% -52.97% -37.88% -41.88% -43.02% -49.42% -31.60% -37.27%
Return on Equity Simple (ROE_SIMPLE)		 -89.88% 0.00% -72.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.49 -7.73 -8.30 -7.46 -8.63 -10 -9.89 -12 -10 -13 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.62% -2.97% -3.87% -2.41% -3.33% -2.33% -1.91% -2.85% -2.72% -2.15% -2.41%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.31% -14.20% -8.11% -10.55% -5.99% -6.24% -8.04% -7.81% -6.80% -7.58%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -11 -11 -12 -11 -12 -14 -14 -17 -15 -19 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -11 -12 -11 -13 -15 -14 -17 -15 -19 -20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.25 0.31 0.78 0.48 0.50 0.65 1.09 0.89 1.39 1.16 1.65
Price to Tangible Book Value (P/TBV)		 0.25 0.31 0.78 0.48 0.50 0.65 1.09 0.89 1.39 1.16 1.65
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 16.44 0.00 0.00 0.00 32.36
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.84 -0.98 -0.94 -0.96 -0.98 -1.00 -0.98 -0.99 -1.00 -1.01 -0.99
Leverage Ratio		 1.10 1.13 1.14 1.11 1.15 1.11 1.09 1.09 1.12 1.08 1.06
Compound Leverage Factor		 1.01 1.04 1.07 0.99 1.05 0.99 0.95 0.99 1.00 0.99 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.46 -1.86 -1.17 0.39 -0.92 3.47 8.78 4.25 6.88 9.03 14.93
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.49 11.17 10.53 16.33 9.85 15.71 18.03 12.82 13.69 14.58 15.69
Quick Ratio		 10.93 10.67 10.04 15.86 9.43 15.54 17.72 12.52 13.39 14.22 15.22
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 22 -11 -6.21 -5.07 -6.00 -4.12 -7.67 -7.96 -8.70 -15 -17
Operating Cash Flow to CapEx		 -17,732.43% 0.00% 0.00% -13,976.36% -105,425.00% 0.00% -33,438.64% -55,681.82% -311,300.00% -70,625.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.92 2.74 3.18 2.47 0.29 -3.16 0.97 -1.19 -1.34 -1.48 3.78
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -29 2.91 -2.08 -2.40 -2.63 -5.90 -2.22 -3.65 -1.63 1.68 2.81
Enterprise Value (EV)		 -55 -44 -9.42 -45 -41 -62 16 -18 50 30 122
Market Capitalization		 19 21 46 44 41 109 173 128 184 228 300
Book Value per Share		 $6.79 $6.01 $5.11 $4.34 $3.66 $8.12 $3.89 $3.42 $3.13 $4.59 $3.15
Tangible Book Value per Share		 $6.79 $6.01 $5.11 $4.34 $3.66 $8.12 $3.89 $3.42 $3.13 $4.59 $3.15
Total Capital		 77 68 58 92 82 167 158 144 132 196 181
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -74 -66 -55 -90 -81 -170 -158 -146 -134 -198 -177
Capital Expenditures (CapEx)		 0.04 0.00 0.00 0.06 0.01 0.00 0.04 0.02 0.00 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.00 -3.02 -2.81 -3.02 -5.06 -9.10 -4.85 -6.89 -6.94 -6.99 -4.71
Debt-free Net Working Capital (DFNWC)		 71 63 52 87 76 161 120 115 126 149 131
Net Working Capital (NWC)		 71 63 52 87 76 161 120 115 126 149 131
Net Nonoperating Expense (NNE)		 2.37 2.49 2.80 2.05 2.59 2.75 2.03 3.35 2.93 3.95 4.04
Net Nonoperating Obligations (NNO)		 -74 -66 -55 -90 -81 -170 -158 -146 -134 -198 -177
Total Depreciation and Amortization (D&A)		 -0.05 -0.01 0.02 0.08 -0.25 -0.20 -0.08 -0.27 -0.31 -0.22 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.87) ($0.90) ($0.97) ($0.45) ($0.50) ($0.25) ($0.29) ($0.35) ($0.31) ($0.39) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 11.35M 11.33M 11.42M 21.23M 22.33M 20.59M 40.71M 42.27M 42.27M 42.84M 57.54M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.50) $0.00 ($0.29) ($0.35) ($0.31) ($0.39) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 11.36M 11.33M 20.59M 20.63M 22.33M 20.59M 40.71M 42.27M 42.27M 42.84M 57.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.36M 11.43M 20.59M 20.63M 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -7.49 -7.73 -8.30 -7.46 -8.63 -10 -9.89 -12 -10 -13 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Protara Therapeutics (NASDAQ: TARA) continues to operate like a clinical-stage biotech: no revenue, persistent net losses, and heavy cash burn. The good news is that the balance sheet still shows a sizeable cash and investment position, giving the company meaningful runway to fund development activities.

  • Q1 2026 ended with $14.7 million in cash and equivalents plus $162.7 million in total investments ($121.0 million short-term and $41.6 million long-term), for a strong liquidity base.
  • Total current assets were $140.0 million versus only $8.9 million in current liabilities, indicating a very strong near-term liquidity position.
  • The company reported $181.2 million in total equity at the end of Q1 2026, which is well above total liabilities of $10.7 million.
  • Interest and investment income of $1.8 million in Q1 2026 helped offset some of the operating loss.
  • Compared with Q1 2025, cash and investments on the balance sheet remain substantial, suggesting the company entered 2026 with ample funding after prior capital raises.
  • Protara recorded no revenue in Q1 2026, and the same was true across the historical quarters provided.
  • Q1 2026 operating expenses were dominated by R&D spending of $13.6 million and SG&A of $6.1 million, consistent with an R&D-focused biotech business model.
  • Quarterly net losses have generally ranged from about $9.9 million to $17.8 million over the periods shown, reflecting ongoing development-stage losses.
  • Diluted shares outstanding have increased over time, which is typical for biotech companies funding operations through equity issuance.
  • Q1 2026 operating cash flow was negative $21.8 million, showing the business is still burning cash at a high rate.
  • Net cash used in investing activities was negative $14.7 million in Q1 2026, driven largely by investment activity rather than productive capital spending.
  • Cash and equivalents fell from $31.5 million in Q2 2025 to $14.7 million in Q1 2026, a notable decline even though total investments remain large.
  • Over the past several quarters, losses have remained persistent with no operating revenue to absorb fixed costs, leaving the company dependent on its cash reserves and market access for funding.

Bottom line: Protara’s financial picture is typical of an early-stage biotech: strong liquidity today, but ongoing losses and cash burn. Investors will likely focus less on near-term profitability and more on clinical progress, financing needs, and how quickly management can advance its pipeline without excessive dilution.

07/22/26 02:08 PM ETAI Generated. May Contain Errors.

Protara Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Protara Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Protara Therapeutics' net income appears to be on an upward trend, with a most recent value of -$57.44 million in 2025, rising from -$21.38 million in 2015. The previous period was -$44.60 million in 2024. See Protara Therapeutics' forecast for analyst expectations on what's next for the company.

Protara Therapeutics' total operating income in 2025 was -$64.55 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $64.55 million

Over the last 10 years, Protara Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Protara Therapeutics' total liabilities were at $13.06 million at the end of 2025, a 8.8% decrease from 2024, and a 215.9% increase since 2015.

In the past 10 years, Protara Therapeutics' cash and equivalents has ranged from $564 thousand in 2019 to $168.60 million in 2020, and is currently $49.66 million as of their latest financial filing in 2025.

Over the last 10 years, Protara Therapeutics' book value per share changed from 3.85 in 2015 to 4.59 in 2025, a change of 19.2%.


Related Companies

Financial statements for NASDAQ:TARA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
NNVC: FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...
Equiscreen | Sponsoredtc pixel
The smarter SpaceX play most investors will miss
There's a classic pattern in every crypto cycle: Bitcoin runs first. Then big altcoins. Then… at the very end…...
Crypto 101 Media | Sponsoredtc pixel
NEW LAW: Congress Approves Setup For Digital Dollar?
On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...
Goldco Direct, LLC | Sponsoredtc pixel
Elon says “don’t save money.” Is he right?
Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...
Freedom Financial | Sponsoredtc pixel
Trump’s emergency dollar reset
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel